ADMA Biologics, Inc. (ADMA)
$
19.84
+0.07 (0.35%)
Key metrics
Financial statements
Free cash flow per share
0.3813
Market cap
4.7 Billion
Price to sales ratio
10.1391
Debt to equity
0.2196
Current ratio
6.5762
Income quality
0.4895
Average inventory
171.2 Million
ROE
0.7239
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
ADMA Biologics, Inc. is a biopharmaceutical company focused on developing, manufacturing, and marketing specialty plasma-derived biologics to address immune deficiencies and infectious diseases both in the United States and internationally. The company recorded a notable revenue of $426,454,000.00 showcasing its steady growth. Among its key offerings are BIVIGAM, an intravenous immune globulin (IVIG) product for treating primary humoral immunodeficiency (PI), ASCENIV, another IVIG product designed for the same condition, and Nabi-HB, indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen along with other potential exposures to Hepatitis B. Additionally, ADMA Biologics is developing a pipeline of plasma-derived therapeutics, including innovative products aimed at the treatment and prevention of S. pneumonia infections for immunoglobulin. The cost of revenue for the company is $206,901,000.00 showcasing its production and operational expenses, while the total costs and expenses for the company are $282,838,000.00 reflecting its overall spending. The company's stock is identified with the symbol 'ADMA' in the market, and the weighted average number of diluted shares outstanding is 243,342,466.00 indicating potential dilution effects. Moreover, the stock is affordable at $19.77 making it suitable for budget-conscious investors seeking opportunities. With a high average trading volume of 3,669,039.00 the stock demonstrates strong liquidity, which is an advantageous factor for traders. With a mid-range market capitalization of $4,736,482,560.00 the company is a steady performer in the biopharmaceutical realm. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape and driving innovation and growth within the Healthcare sector. This dual focus on patient needs and robust market engagement aligns ADMA Biologics as an important entity shaping the future of plasma-derived therapeutics.
Is ADMA Biologics, Inc. (ADMA) a good investment?
Investing in ADMA Biologics, Inc. (ADMA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bearish outlook. Always conduct your own research before investing.
What is ADMA Biologics, Inc. (ADMA)'s stock forecast?
Analysts predict ADMA Biologics, Inc. stock to fluctuate between $9.63 (low) and $25.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is ADMA Biologics, Inc.'s market capitalization?
As of 2025-05-30, ADMA Biologics, Inc.'s market cap is $4,736,482,560, based on 238,734,000 outstanding shares.
How does ADMA Biologics, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., ADMA Biologics, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy ADMA Biologics, Inc. (ADMA) stock?
To buy ADMA Biologics, Inc. (ADMA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ADMA. Place an order (Market, Limit, etc.).
What is the best time to invest in ADMA Biologics, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did ADMA Biologics, Inc. perform in the last earnings report?
Revenue: $426,454,000 | EPS: $0.85 | Growth: -753.85%.
Where can I find ADMA Biologics, Inc.'s investor relations reports?
Visit https://www.admabiologics.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for ADMA Biologics, Inc.?
You can explore historical data from here
What is the all-time high and low for ADMA Biologics, Inc. stock?
All-time high: $25.67 (2025-04-28) | All-time low: $1.01 (2021-10-21).
What are the key trends affecting ADMA Biologics, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
At current levels, GRFS scores over ADMA with cheaper valuation, a broad portfolio, and strong EPS growth estimates despite the latter's robust Asceniv-driven momentum.
seekingalpha.com
ADMA Biologics has demonstrated significant revenue growth, margin expansion, and profitability, leading to a 1,314% increase in share price since 2021. The company's Q1 performance showed a 40% YoY revenue increase, strong demand for ASCENIV, and improved gross profit margins. ADMA's financial health is robust, with $171M in cash and receivables, reduced debt costs, and a new $500M share repurchase program.
zacks.com
ADMA Biologics misses on Q1 earnings and revenues. Nonetheless, the growth prospects remain strong as the company raises its revenue guidance for 2025.
seekingalpha.com
ADMA Biologics, Inc. (NASDAQ:ADMA ) Q1 2025 Earnings Conference Call May 7, 2025 4:30 PM ET Company Participants Skyler Bloom - Senior Director, Business Development and Corporate Strategy Adam Grossman - Founder, Director, President and Chief Executive Officer Brad Tade - Chief Financial Officer and Treasurer Conference Call Participants Anthony Petrone - Mizuho Group Rick Miller - Cantor Fitzgerald Gary Nachman - Raymond James Operator Good afternoon and welcome to the ADMA Biologics First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 7, 2025. At this time, all participants are in a listen-only mode.
marketbeat.com
While major market indexes like the S&P 500 have struggled to gain traction in 2025 and remain in the red YTD, certain pockets of the market are showing impressive strength. Several medical and biotechnology sector mid-cap stocks have stood out for their resilience and outperformance.
zacks.com
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
zacks.com
Adma Biologics (ADMA) concluded the recent trading session at $23.52, signifying a +1.07% move from its prior day's close.
zacks.com
Strong performance of Asceniv continues to boost ADMA. We recommend the stock to investors due to its solid long-term fundamentals.
zacks.com
Here is how Adma Biologics (ADMA) and Agilon Health (AGL) have performed compared to their sector so far this year.
zacks.com
If you are looking for stocks that are well positioned to maintain their recent uptrend, Adma Biologics (ADMA) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
See all news
